Participated · Series A · Jan 2023

KeyCare is a Chicago-based national virtual care organization built on the Epic electronic health record platform. Its technology integrates directly into existing clinical workflows and data infrastructure, enabling health systems to offer virtual visits that are coordinated with in-person care. By embedding into Epic, KeyCare helps providers maintain continuity of records, scheduling, and billing while giving patients a seamless telehealth experience. The company focuses on improving patient and clinician satisfaction through streamlined virtual encounters and robust data sharing. With new capital, KeyCare plans to deepen its investment in AI-enabled capabilities, enhance its platform features, and scale operational capacity to meet rising demand from health-system partners. To date, the company has raised more than $55 million.

Led · Seed · Mar 2020

Professional Credentials Exchange (ProCredEx) operates a digital marketplace that enables member healthcare organizations to securely share, exchange, and monetize credential verification data. The platform leverages distributed ledger technology, advanced data science, and machine learning to streamline credentialing workflows within a secure community. ProCredEx was formed two years ago as a joint venture between Hashed Health and Tenon Consulting Solutions and is led by CEO Anthony Begando. The company has secured a multifaceted partnership with enterprise software firm R3, including a license to build the marketplace on R3’s Corda Enterprise distributed ledger platform. Its core product targets credentialing organizations seeking secure, monetizable data exchange. Financially, ProCredEx completed an initial $3.5M seed funding round to support product development and marketplace rollout.

Participated · Series B · Jun 2019

Vynca provides technology and interdisciplinary care teams to support people living with serious illnesses and to improve experiences for patients and caregivers before and during end‑of‑life transitions. The company partners with healthcare providers, payers and risk‑bearing entities to serve populations including those with congestive heart failure, cancer and end‑stage renal disease. Vynca’s solutions aim to enable clinicians and partners to achieve better outcomes while allowing organizations to enter value‑based care arrangements. The firm highlights the scale of need—more than $205B is spent annually in the U.S. during end‑of‑life transitions—and seeks to expand access nationally. With new capital, Vynca plans to grow its clinical services organization and expand its technology suite to meet the needs of value‑based care programs as well as traditional care paradigms. Vynca provides an end-to-end advance care planning solution that helps health care organizations implement and scale advance care planning. Its technology supports education and engagement in advance care planning conversations, shared decision making, digital completion of documents, and ensures universal document accessibility across the care continuum. The company partners with over 80 hospitals, as well as health plans, ACOs, and five state registries. Led by co-founder and CEO Ryan Van Wert, M.D., Vynca plans to use new funding to expand into new geographies and develop new products. The company recently secured $10.3M in Series B financing to support that expansion and product development. The funding and partnerships aim to increase adoption and accessibility of advance care planning across provider networks.

Participated · Series C · Oct 2018

Gauss Surgical provides Triton, a platform that measures surgical blood loss in real time on the iPad using digital imaging and machine learning. The company has received de novo approval from the U.S. Food and Drug Administration and a European CE mark for the device. Triton has been adopted by 50 hospitals that together perform more than 200,000 infant deliveries each year. Gauss plans to use new funding to accelerate Triton adoption in hospitals and to develop additional AI-driven applications for the operating room. The company is led by founder and CEO Siddarth Satish and is based in Los Altos, California. Its recent financing improves its runway to scale clinical deployment and product development. Gauss Surgical developed Triton, a real-time platform for monitoring surgical blood loss that combines computer vision and machine learning. Triton supplies clinicians with accurate blood loss assessments to support surgical decision-making. The platform holds four FDA clearances and has received CE Mark approval. Triton is in clinical use at several U.S. health systems including HackensackUMC, Cedars-Sinai Medical Center, the MemorialCare Health System, and UC Irvine Medical Center. The company is led by founder and CEO Siddarth Satish and recently closed a $12.6M Series B. Gauss has raised $24.6M in total funding to date. Gauss Surgical develops a digital health app that quantifies surgical blood loss by measuring blood collected in canisters. The app received FDA 510(k) clearance a few months before the latest fundraise. Management says the tool can help reduce clinical and staff burnout by automating blood-loss measurement. Target use cases called out include obstetrics, patients with severe burns, and procedures prone to heavy blood loss such as orthopedic, cardiovascular, and pediatric surgery. The company has seen rising interest from prospective corporate and strategic investors exploring digital health solutions for hospitals. Gauss plans to use new funding to support sales and marketing for the app rollout.

Participated · Equity · Jun 2017

Orig3n is a Boston-based biotech research company focused on genetics and regenerative medicine. It provides consumers access to genetic information to enable proactive, personalized health choices and conducts R&D into cell therapies. The company invests in cellular science to develop personalized therapies for repairing tissue damage and disease. Orig3n maintains a large allogeneic bank of cells that is HLA-matched to 90% of the U.S. population, which underpins its regenerative-medicine programs. It plans to use recent funding to expand domestically and internationally and to continue R&D to advance its regenerative treatments. As of the Series B, Orig3n has raised over $50 million since its 2014 founding. ORIG3N focuses on genetics and regenerative medicine, offering a line of direct-to-consumer genetic tests while advancing cellular science to develop personalized therapies. The company operates what it describes as a fully-matched allogeneic cell bank and is intensifying research into cell therapies. ORIG3N emphasizes community‑driven, patient-fueled research and cultivates engagement through events and educational initiatives. Management says the company is increasingly consumer-facing and aims to accelerate the future of regenerative medicine. ORIG3N was founded in 2014 and is positioning its research and community assets to support therapeutic development. Financially, the company has raised over $30 million in capital to date. Orig3n is a Boston, MA-based biotech company that develops a disease-modeling platform targeting rare and genetically inherited diseases using iPSC-derived differentiated cells. The company closed a $12.5m Series A financing to advance its programs. It will use the funds to launch LifeSystems™ cellular models created from its LifeCapsule™ bio-repository. Orig3n launched the LifeCapsule bio-repository, a living database and large bank of induced pluripotent stem cells to which anyone can contribute. The platform is intended to advance screening projects and deliver data to inform therapeutic decisions, aiming to replace trial-and-error approaches to treating disease. Orig3n was founded in 2014 by Robin Y. Smith. ORIG3N, based in Boston, MA, is developing a disease-modeling platform targeting rare genetically inherited diseases. Led by CEO and co-founder Robin Y. Smith, the company’s core product is the Life Capsule™, a bio-repository open to public contribution. The Life Capsule collects a small amount of blood and reprograms cells into induced pluripotent stem cells (iPSCs). These iPSCs are used for disease modeling outside the body to support critical medical research and potential individualized therapy. The company intends to use the newly raised funds to expand its Life Capsule offering. ORIG3N recently raised $3.1M in funding from institutional backers.